Blinking and schizotypal thinking

Journal of Psychopharmacology

Volumn 19, Issue 5, 2005, Pages 513-520

  Mohr, Christine ^a,b   Sandor P S ^a,c   Landis, T ^d   Fathi, M ^d   Brugger, P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Dopamine; High risk; Magical Ideation; Physical Anhedonia; Spontaneous eye blink rate; Symptoms

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; DOPAMINE; LEVODOPA; PLACEBO;

ADULT; ARTICLE; BLINKING; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC ACTIVITY; EYELID REFLEX; HIGH RISK PATIENT; HUMAN; HUMAN EXPERIMENT; MALE; NERVE CELL NETWORK; NORMAL HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOTYPAL PERSONALITY DISORDER;

EID: 25844484488     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105056538     Document Type: Article

References (80)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin R M, Seibyl J P, Bowers M, van Dyck C H, Charney D S, Innis R B, Lamelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761-767
2. Agostino R, Berardelli A, Cruccu G, Stocchi F, Manfredi M (1987) Corneal and blink reflexes in Parkinson's disease with 'on-off' fluctuations. Mov Disord 2: 227-235
3. Arnsten A F (1997) Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11: 151-162
4. Barnes T R, McPhillips M A (1995) How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. Int Clin Psychopharmacol 10(Suppl 3): 115-121
5. Barnett K J, Corballis M C (2002) Ambidexterity and magical ideation. Laterality 7: 75-84
6. Bentivoglio A R, Bressman S B, Cassetta E, Carretta D, Tonali P, Albanese A (1997) Analysis of blink rate patterns in normal subjects. Mov Disord 12: 1028-1034
7. Blin O, Masson G, Azulay J P, Fondarai J, Serratrice G (1990) Apomorphine-induced blinking and yawning in healthy volunteers. Br J Clin Pharmacol 30: 769-773
8. Brown A S, Gershon S (1993) Dopamine and depression. J Neural Transm 91: 75-109
9. Campbell J J (2000) Neuropsychiatric assessment. In Coffey C E, Cummings J L (eds), Textbook of Geriatric Neuropsychiatry, 2nd edn. American Psychiatric Press, Washington, DC, pp. 109-124
10. Chapman L J, Chapman J P (1987) The measurement of handedness. Brain Cogn 6: 175-183
11. Chapman L J, Chapman J P, Kwapil T R, Eckblad M, Zinser M C (1994) Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol 103: 171-183
12. Chapman L J, Chapman J P, Raulin M L (1976) Scales for physical and social anhedonia. J Abnorm Psychol 85: 374-382
13. Chapman L J, Edell W S, Chapman J P (1980) Physical anhedonia, perceptual aberration, and psychosis proneness. Schizophr Bull 6: 639-653
14. Chen E Y, Lam L C, Chen R Y, Nguyen D G (1996) Blink rate, neurocognitive impairments, and symptoms in schizophrenia. Biol Psychiatry 40: 597-603
15. Cornblatt B A, Lencz T, Smith C W, Correll C U, Auther A M, Nakayama E (2003) The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull 29: 633-651
16. Davis K L, Kahn R S, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-1486
17. de Haan L, Lavalaye J, Linszen D, Dingemans P M, Booij J (2000) Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 157: 1019-1020
18. Depue R A, Luciana M, Arbisi P, Collins P, Leon A (1994) Dopamine and the structure of personality: relation of agonist-induced dopamine activity to positive emotionality. J Pers Soc Psychol 67: 485-498
19. Ebert D, Feistel H, Kaschka W, Barocka A, Pirner A (1994) Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation - preliminary results. Biol Psychiatry 35: 880-885
20. Ebert D, Albert R, Hammon G, Strasser B, May A, Merz A (1996) Eye-blink rates and depression. Is the antidepressant effect of sleep deprivation mediated by the dopamine system? Neuropsychopharmacology 15: 332-339
21. Eckblad M, Chapman L J (1983) Magical ideation as an indicator of schizotypy. J Consult Clin Psychol 51: 215-225
22. Elsworth J D, Lawrence M S, Roth R H, Taylor J R, Mailman R B, Nichols D E, Lewis M H, Redmond D E Jr (1991) D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J Pharmacol Exp Ther 259: 595-600
23. Evinger C, Basso M A, Manning K A, Sibony P A, Pellegrini J J, Horn A K (1993) A role for the basal ganglia in nicotinic modulation of the blink reflex. Exp Brain Res 92: 507-515
24. Fleischhacker W (2000) Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. Encephale 26: 12-14
25. Fleming K, Bigelow L B, Weinberger D R, Goldberg T E (1995) Neuropsychological effects of amphetamine may correlate with personality characteristics. Psychopharmacol Bull 31: 357-362
26. Fukuda K (1994) Analysis of eyeblink activity during discriminative tasks. Percept Mot Skills 79: 1599-1608
27. Garety P, Wessely S (1994) The assessment of positive symptoms. In Barnes T R E, Nelson H E (eds), The Assessment of Psychoses. A Practical Handbook. Chapman and Hall, London, UK, pp. 21-39
28. Gasser U E, Jorga K, Crevoisier C, Hovens S E, van Giersbergen P L (1999) COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide: a novel principle in the treatment of Parkinson's disease. Eur Neurol 41: 206-211
29. Goldberg T E, Bigelow L B, Weinberger D R, Daniel D G, Kleinman J E (1991) Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 148: 78-84
30. Gooding D C, Kwapil T R, Tallent K A (1999) Wisconsin Card Sorting Test deficits in schizotypic individuals. Schizophr Res 40: 201-209
31. Guillem F, Bicu M, Bloom D, Wolf M A, Desautels R, Lalinec M, Kraus D, Debruille J B (2001) Neuropsychological impairments in the syndromes of schizophrenia: a comparison between different dimensional models. Brain Cogn 46: 153-159
32. Gunduz H, Wu H, Ashtari M, Bogerts B, Crandall D, Robinson D G, Alvir J, Lieberman J, Kane J, Bilder R (2002) Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects. Biol Psychiatry 51: 801-808
33. Hall A A (1945) The origin and purpose of blinking. Br J Ophthalmol 29: 445-467
34. Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Eronen E, Ruotsalainen U, Salokangas R K (1999) Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 35: 41-50
35. Holland M K, Tarlow G (1972) Blinking and mental load. Psychol Rep 31: 119-127
36. Isella V, Iurlaro S, Piolti R, Ferrarese C, Frattola L, Appollonio I, Melzi P, Grimaldi M (2003) Physical anhedonia in Parkinson's disease. J Neurol Neurosurg Psychiatry 74: 1308-1311
37. Jacobsen L K, Hommer D W, Hong W L, Castellanos F X, Frazier J A, Giedd J N, Rapoport J L (1996) Blink rate in childhood-onset schizophrenia: comparison with normal and attention-deficit hyperactivity disorder controls. Biol Psychiatry 40: 1222-1229
38. Jeste D V, Zalcman S, Weinberger D R, Cutler N R, Bigelow L B, Kleinman J E, Rogol A, Wyatt R J (1983) Apomorphine response and subtyping of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 7: 83-88
39. Karson C N, Berman K F, Donnelly E F, Mendelson W B, Kleinman J E, Wyatt R J (1981) Speaking, thinking, and blinking. Psychiatry Res 5: 243-246
40. Karson C N (1983) Spontaneous eye-blink rates and dopaminergic systems. Brain 106: 643-653
41. Karson C N, Berman K F, LeWitt P A, Burns S, Newman R P, Wyatt R J (1983) Blink rates: neuropharmacological and clinical evidence of dopaminergic control. Psychopharmacol Bull 19: 620-622
42. Karson C N, Dykman R A, Paige S R (1990) Blink rates in schizophrenia. Schizophr Bull 16: 345-354
43. Kerrison J B, Lancaster J L, Zamarripa F E, Richardson L A, Morrison J C, Holck D E, Andreason K W, Blaydon S M, Fox P T (2003) Positron emission tomography scanning in essential blepharospasm. Am J Ophthalmol 136: 846-852
44. Kitamura T, Kahn A, Kumar R, Macintosh J H (1984) Blink rate and blunted affect among chronic schizophrenic patients. Biol Psychiatry 19: 429-434
45. Klein C, Berg P, Rockstroh B, Andresen B (1999) Topography of the auditory P300 in schizotypal personality. Biol Psychiatry 45: 1612-1621
46. Kleven M S, Koek W (1996) Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys. J Pharmacol Exp Ther 279: 1211-1219
47. Knable M B, Egan M F, Heinz A, Gorey J, Lee K S, Coppola R, Weinberger D R (1997) Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia: [123I]-iodobenzamide SPECT study. Br J Psychiatry 171: 574-577
48. Kosslyn S M, Cacioppo J T, Davidson R J, Hugdahl K, Lovallo W R, Spiegel D, Rose R (2002) Bridging psychology and biology: the analysis of individuals in groups. Am Psychol 57: 341-351
49. Loas G, Boyer P, Legrand A (1999) Anhedonia in the deficit syndrome of schizophrenia. Psychopathology 32: 207-219
50. Mackert A, Woyth C, Flechtner K, Volz H (1990) Increased blink rate in drug-naive acute schizophrenic patients. Biol Psychiatry 27: 1197-1202
51. McGlone J (1980) Sex differences in human brain asymmetry: a critical survey. Behav Brain Sci 3: 215-263
52. Mehta M A, Owen A M, Sahakian B J, Mavaddat N, Pickard J D, Robbins T W (2000) Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 20: RC65
53. Meyer T D, Hautzinger M (1999) Two year stability of psychosis proneness scales and their relationship to personality disorder traits. J Pers Assess 73: 472-488
54. Mohr C, Bracha H S, Brugger P (2003a) Magical Ideation modulates spatial behavior. J Neuropsychiatry Clin Neurosci 15: 168-174
55. Mohr C, Thut G, Landis T, Brugger P (2003b) Hands, arms, and minds: Interactions between posture and thought. J Clin Exp Neuropsychol 25: 1000-1010
56. Mohr C, Landis T, Sandor P S, Fathi M, Brugger P (2004) Non-stereotyped responding in positive schizotypy after a single dose of levodopa. Neuropsychopharmacology 29: 1741-1751
57. Mohr C, Landis T, Bracha H S, Fathi M, Brugger P (2005a) Levodopa reverses gait asymmetries related to anhedonia and magical thinking. Eur Arch Psychiatry Clin Neurosci. 255: 33-39
58. Mohr C, Krummenacher P, Landis T, Sandor P S, Fathi M, Brugger P (2005b) Levodopa improves word recognition in 'Anhedonics' but not in 'Magics'. J Psychiatric Res 39: 241-250
59. Nilsson F M, Kessing L V, Sorensen T M, Andersen P K, Bolwig T G (2002) Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand 106: 202-211
60. Park S (1999) Hemispheric asymmetry of spatial working memory deficit in schizophrenia. Int J Psychophysiol 34: 313-322
61. Pizzagalli D, Lehmann D, Gianotti L, Koenig T, Tanaka H, Wackermann J, Brugger P (2000) Brain electric correlates of strong belief in paranormal phenomena: intracerebral EEG source and regional Omega complexity analyses. Psychiatry Res 100: 139-154
62. Rammsayer T H (1998) Extraversion and dopamine: individual differences in response to changes in dopaminergic activity as a possible biological basis of extraversion. Eur Psychol 3: 37-50
63. Sarkin A J, Dionisio D P, Hillix W A, Granholm E (1998) Positive and negative schizotypal symptoms relate to different aspects of crossover reaction time task performance. Psychiatry Res 81: 241-249
64. Scherbarth-Roschmann P, Hautzinger M (1991) Zur psychometrischen Erfassung von Schizotypie: Methodische Überprüfung und erste Validierung von zwei Skalen zur Erfassung von Risikomerkmalen. Z Klin Psychol 20: 238-250
65. Schroder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S, Geider F J, Sauer H (1998) D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment. Biol Psychiatry 43: 660-665
66. Schürhoff F, Szoke A, Bellivier F, Turcas C, Villemur M, Tignol J, Rouillon F, Leboyer M (2003) Anhedonia in schizophrenia: a distinct familial subtype? Schizophr Res 61: 59-66
67. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158: 1206-1214
68. Sigmundsson T, Suckling J, Maier M, Williams S, Bullmore E, Greenwood K, Fukuda R, Ron M, Toone B (2001) Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry 158: 234-243
69. Stevens J (1978) Eye blink and schizophrenia: psychosis or tardive dyskinesia. Am J Psychiatry 135: 223-226
70. Strakowski S M, Sax K W, Setters M J, Keck P E Jr (1996) Enhanced response to repeated d-amphetamine challenge: evidence for behavioral sensitization in humans. Biol Psychiatry 40: 872-880
71. Strakowski S M, Sax K W, Setters M J, Stanton S P, Keck P E Jr (1997) Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans. Biol Psychiatry 42: 749-755
72. Taylor J R, Elsworth J D, Lawrence M S, Sladek J R Jr, Roth R H, Redmond D E Jr (1999) Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTP-treated monkeys. Exp Neurol 158: 214-220
73. Taylor K I, Zäch P, Brugger P (2002) Why is magical ideation related to leftward deviation on an implicit line bisection task? Cortex 38: 247-252
74. van der Post J, de Waal P P, de Kam M L, Cohen A F, van Gerven J M (2004) No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity. J Psychopharmacol 18: 109-114
75. Wetzel H, Hillert A, Grunder G, Benkert O (1994) Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am J Psychiatry 151: 1499-1502
76. Wible C G, Anderson J, Shenton M E, Kricun A, Hirayasu Y, Tanaka S, Levitt J J, O'Donnell B F, Kikinis R, Jolesz F A, McCarley R W (2001) Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. Psychiatry Res 108: 65-78
77. Williams G V, Goldman-Rakic P S (1995) Modulation of memory-fields by dopamine D1 receptors in prefrontal cortex. Nature 376: 572-575
78. Willner P (1995) Dopaminergic mechanisms in depression and mania. In Bloom F E, Kupfer D J (eds), Psychopharmacology: the Fourth Generation of Progress. Raven Press, New York, pp. 921-931
79. Wood J, Hassett J (1983) Eyeblinking during problem solving: the effect of problem difficulty and internally vs. externally directed attention. Psychophysiology 20: 18-20
80. Zaman M L, Doughty M J, Button N F (1998) The exposed ocular surface and its relationship to spontaneous eyeblink rate in elderly caucasians. Exp Eye Res 67: 681-686